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Introduction
Headaches recur in up to 87% of migraine patients visiting
the emergency department (ED), making ED recidivism a
management challenge.
Aims
We aimed herein to determine the role of corticosteroids
in the acute management of migraine in the ED and out-
patient care.
Methods
A PubMed search was employed for Clinical Studies and
Systematic Reviews on the PubMed Clinical Queries tool
combining the terms ‘migraine’ and ‘corticosteroids’ from
1980 until May 1, 2014.
Results
Twenty-two studies (n = 2203, 50% ED-based, 64% rando-
mized-controlled) and four systematic reviews were
included. International Classification of Headache Disor-
ders criteria were applied in 68%. Twenty-one studies indi-
cated observed outcome differences favoring benefits of
corticosteroid administration. Median absolute risk reduc-
tion was 30% (range 6 - 48.2%) and 11% (6 - 48.6%) for
24- and 72-hour headache recurrence, respectively. Par-
enteral dexamethasone was the most commonly (65%)
administered steroid, at an average single dose of 12.8 mg
(range 4 - 24 mg). All meta-analyses revealed efficacy of
adjuvant corticosteroids to various abortive medications –
indicating generalizability. Adverse effects were tolerable.
Higher disability, status migrainosus, incomplete pain
relief, and previous history of headache recurrence
predicted outcome favourability.
Conclusions
Our literature review suggests that with corticosteroid
treatment, recurrent headaches become milder than pre-
treated headaches and later respond to nonsteroidal ther-
apy. Single-dose intravenous dexamethasone provides
reasonable option for managing resistant, severe, or pro-
longed migraine attacks; recommendations include 6-8
administrations per year with follow up of adverse effects.
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